EP1542721A4 - MODIFIED "S" ANTIBODIES - Google Patents

MODIFIED "S" ANTIBODIES

Info

Publication number: EP1542721A4
Authority: EP; European Patent Office
Prior art keywords: antibodies; modified
Prior art date: 2002-06-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP03760235A

Other languages

German (de)

French (fr)

Other versions

EP1542721A1 (en

Inventor

Bernie Scallon

Ann Cai

Michael Naso

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Biotech Inc

Original Assignee

Centocor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-14

Filing date

2003-06-05

Publication date

2007-05-02

2003-06-05 Application filed by Centocor Inc filed Critical Centocor Inc

2005-06-22 Publication of EP1542721A1 publication Critical patent/EP1542721A1/en

2007-05-02 Publication of EP1542721A4 publication Critical patent/EP1542721A4/en

Status Withdrawn legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP03760235A 2002-06-14 2003-06-05 MODIFIED "S" ANTIBODIES Withdrawn EP1542721A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38889602P	2002-06-14	2002-06-14
PCT/US2003/017742 WO2003105898A1 (en)	2002-06-14	2003-06-05	Modified "s" antibodies
US388896P		2010-10-01

Publications (2)

Publication Number	Publication Date
EP1542721A1 EP1542721A1 (en)	2005-06-22
EP1542721A4 true EP1542721A4 (en)	2007-05-02

Family

ID=29736560

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP03760235A Withdrawn EP1542721A4 (en)	2002-06-14	2003-06-05	MODIFIED "S" ANTIBODIES

Country Status (6)

Country	Link
US (1)	US7427471B2 (en)
EP (1)	EP1542721A4 (en)
JP (1)	JP2008522583A (en)
AU (1)	AU2003253621A1 (en)
CA (1)	CA2489280A1 (en)
WO (1)	WO2003105898A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2511910A1 (en) *	2002-12-27	2004-07-15	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CN1838968A (en)	2003-08-08	2006-09-27	艾伯吉尼斯公司	Antibodies aimed to parathyroid hormone (PTH) and uses thereof
US7318925B2 (en)	2003-08-08	2008-01-15	Amgen Fremont, Inc.	Methods of use for antibodies against parathyroid hormone
SI2066351T1 (en) *	2006-10-02	2016-02-29	E.R. Squibb & Sons, L.L.C.	Human antibodies that bind cxcr4 and uses thereof
SI2185589T1 (en)	2007-06-01	2016-04-29	University Of Maryland Baltimore	Immunoglobulin constant region fc receptor binding agents
CA2683801A1 (en)	2007-06-06	2008-12-11	Domantis Limited	Polypeptides, antibody variable domains and antagonists
US20100153463A1 (en) *	2008-12-15	2010-06-17	Honeywell International Inc.	run-time database redirection system
US20130012916A1 (en) *	2010-02-11	2013-01-10	Glide Pharmaceutical Technologies Limited	Delivery of immunoglobulin variable domains and constructs thereof
WO2012016073A2 (en)	2010-07-28	2012-02-02	Gliknik Inc.	Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
KR20150058236A (en)	2012-08-20	2015-05-28	글리크닉 인코포레이티드	Molecules with antigen binding and polyvalent fc gamma receptor binding activity
JP2017505348A (en)	2014-02-10	2017-02-16	パタラファーマリミテッドライアビリティカンパニー	Mast cell stabilizer for the treatment of lung diseases
PL3104853T3 (en)	2014-02-10	2020-05-18	Respivant Sciences Gmbh	TREATMENT OF SYSTEMIC DISORDERS WITH TORSION CELL STABILIZERS
CN104408321A (en) *	2014-12-04	2015-03-11	环境保护部南京环境科学研究所	Method for forecasting reproduction toxicity of phenol compounds to daphnia magna
IL309260B2 (en)	2015-07-24	2025-01-01	Gliknik Inc	Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
US10265296B2 (en)	2015-08-07	2019-04-23	Respivant Sciences Gmbh	Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en)	2015-08-07	2017-02-16	Patara Pharma, LLC	Methods for the treatment of mast cell related disorders with mast cell stabilizers
CA3026420A1 (en)	2016-06-07	2017-12-14	Gliknik Inc.	Cysteine-optimized stradomers
JP2019528320A (en)	2016-08-31	2019-10-10	レシュピファントサイエンシスゲゼルシャフトミットベシュレンクターハフトゥングＲｅｓｐｉｖａｎｔＳｃｉｅｎｃｅｓＧｍｂｈ	Cromolyn composition for the treatment of chronic cough due to idiopathic pulmonary fibrosis
EP3522983A4 (en)	2016-10-07	2020-06-03	Respivant Sciences GmbH	CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
BR112019009484A2 (en)	2016-12-09	2019-07-30	Gliknik Inc	manufacturing optimization of gl-2045, a multimerizer stradomer
BR112019009495A2 (en)	2016-12-09	2019-08-06	Gliknik Inc	methods of treating inflammatory disorders with multivalent fc compounds
CN109609596A (en) *	2018-12-17	2019-04-12	依科赛生物科技（太仓）有限公司	A kind of free DNA blood preservative for preventing hemolysis and its application
KR20200099807A (en) *	2019-02-15	2020-08-25	아주대학교산학협력단	Antibody Fragment With Constant Region of Antibody and Uses Thereof
JP7627413B2 (en) *	2020-08-21	2025-02-06	ファチアブジェンインコーポレイテッド	Antibody fragments consisting of heavy and light chain constant regions in which a gamma constant region (Cγ1) and an epsilon constant region (Cε2-4) are fused, and uses thereof
CN115851826B (en) *	2023-01-31	2023-11-24	昆明理工大学	Application of glutamine synthetase in improving formaldehyde absorption and metabolism capability of plants

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000009560A2 (en) *	1998-08-17	2000-02-24	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US644792A (en) *	1899-09-14	1900-03-06	Stanhope Boal	Heater.
ATE171042T1 (en) *	1989-08-01	1998-10-15	Scripps Research Inst	METHODS AND COMPOSITIONS FOR IMPROVING THE SYMPTOMS OF SEPSIS
US5959177A (en) *	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US5595177A (en) *	1994-06-03	1997-01-21	Harbor-Ucla Research And Education Institute, Inc.	Scintigraphy guided stereotaxic localizations apparatus for breast carcinomas
US5834597A (en) *	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3655899A (en) *	1998-04-20	1999-11-08	Regents Of The University Of California, The	Modified immunoglobulin molecules and methods for use thereof

2003
- 2003-06-05 AU AU2003253621A patent/AU2003253621A1/en not_active Abandoned
- 2003-06-05 JP JP2004512799A patent/JP2008522583A/en active Pending
- 2003-06-05 WO PCT/US2003/017742 patent/WO2003105898A1/en not_active Ceased
- 2003-06-05 EP EP03760235A patent/EP1542721A4/en not_active Withdrawn
- 2003-06-05 CA CA002489280A patent/CA2489280A1/en not_active Abandoned
- 2003-06-05 US US10/454,948 patent/US7427471B2/en not_active Expired - Lifetime

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000009560A2 (en) *	1998-08-17	2000-02-24	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CAVACINI L A ET AL: "Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 155, 1995, pages 3638 - 3644, XP002970809, ISSN: 0022-1767 *
GREENWOOD J ET AL: "ENGINEERING MULTIPLE-DOMAIN FORMS OF THE THERAPEUTIC ANTIBODY CAMPATH-1H: EFFECTS ON COMPLEMENT LYSIS", THERAPEUTIC IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBL. LONDON, GB, vol. 1, no. 5, October 1994 (1994-10-01), pages 247 - 255, XP009059035, ISSN: 0967-0149 *
ISOGAI EMIKO ET AL: "Therapeutic effect of anti-TNF-alpha antibody and levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection", COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, vol. 24, no. 4, October 2001 (2001-10-01), pages 217 - 231, XP002424158, ISSN: 0147-9571 *
KADOKAMI T ET AL: "Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model.", CIRCULATION 4 SEP 2001, vol. 104, no. 10, 4 September 2001 (2001-09-04), pages 1094 - 1097, XP002424160, ISSN: 1524-4539 *
MA J K-C ET AL: "ASSEMBLY OF MONOCLONAL ANTIBODIES WITH IGG1 AND IGA HEAVY CHAIN DOMAINS IN TRANSGENIC TOBACCO PLANTS", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 24, no. 1, January 1994 (1994-01-01), pages 131 - 138, XP002003170, ISSN: 0014-2980 *
SCALLON BERNARD ET AL: "Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency", MOLECULAR IMMUNOLOGY, vol. 41, no. 1, May 2004 (2004-05-01), pages 73 - 80, XP002424159, ISSN: 0161-5890 *
See also references of WO03105898A1 *

Also Published As

Publication number	Publication date
WO2003105898A1 (en)	2003-12-24
EP1542721A1 (en)	2005-06-22
US7427471B2 (en)	2008-09-23
JP2008522583A (en)	2008-07-03
US20030232046A1 (en)	2003-12-18
CA2489280A1 (en)	2003-12-24
AU2003253621A1 (en)	2003-12-31

Legal Events

Date	Code	Title	Description
2005-05-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2005-06-22	17P	Request for examination filed	Effective date: 20050112
2005-06-22	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
2005-06-22	AX	Request for extension of the european patent	Extension state: AL LT LV MK
2005-10-05	DAX	Request for extension of the european patent (deleted)
2007-05-02	A4	Supplementary search report drawn up and despatched	Effective date: 20070403
2007-05-02	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/24 20060101ALN20070326BHEP Ipc: A61P 31/00 20060101ALI20070326BHEP Ipc: C12N 5/10 20060101ALI20070326BHEP Ipc: C12N 15/85 20060101ALI20070326BHEP Ipc: C12N 15/13 20060101ALI20070326BHEP Ipc: C07K 16/00 20060101ALI20070326BHEP Ipc: A61K 39/395 20060101AFI20040108BHEP
2007-09-19	17Q	First examination report despatched	Effective date: 20070820
2009-06-26	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2009-08-12	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: CENTOCOR ORTHO BIOTECH INC.
2010-04-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2010-05-19	18D	Application deemed to be withdrawn	Effective date: 20091120

Publication	Publication Date	Title
EP1501856A4 (en)	2007-06-06	ANTI-HER2 ANTIBODY VARIANTS
EP1423431A4 (en)	2005-04-27	ANTI-VLA-1 ANTIBODIES
EP1396500A4 (en)	2005-02-02	ANTI-TRAIL-R ANTIBODIES
FR18C1024I2 (en)	2019-05-17	HETEROCYCLOCARBOXAMIDE DERIVATIVES
EP1616881A4 (en)	2008-08-27	ANTI-MPL ANTIBODIES
MA29014B1 (en)	2007-11-01	ANTIBODY FORMULATIONS
FR16C1012I2 (en)	2019-01-11	THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
EP1490110A4 (en)	2006-12-27	ANTI-ALPHA V BETA 6 ANTIBODIES
FR10C0050I2 (en)	2011-12-30	OPGL ANTIBODIES
IS6779A (en)	2003-04-11	Human antibody against LT-beta-R
AU2003253621A1 (en)	2003-12-31	Modified "s" antibodies
ITTO20030640A1 (en)	2005-02-20	MAN INTERFACE SYSTEM - MACHINE USING
EP1680666A4 (en)	2008-03-26	ANTI-THERAPEUTIC HUMAN ANTIBODY DETECTION
EE200300569A (en)	2004-04-15	CD44v6-specific antibodies
EP1293850A4 (en)	2006-05-03	INFORMATION PROCESSOR
DK1487778T3 (en)	2012-08-06	Substituted 4 aminocyclohexanols
EP1646401A4 (en)	2007-07-18	SPECIFIC HUMAN ANTIBODIES
MA27184A1 (en)	2005-01-03	ANTI-INGAP ANTIBODY ASSAY
DE50208629D1 (en)	2006-12-21	pedal
ITPD20020251A1 (en)	2004-04-02	DEVICE FOR THE OPTIMIZATION OF THE GRAFT OF
FR2847999B1 (en)	2005-02-11	BINDING MODELING SOFTWARE
FR2833498B3 (en)	2003-10-31	STAIRS SIMULATOR
DE60207900D1 (en)	2006-01-19	"Suspend" -Paketübertrager
EP1501350A4 (en)	2006-08-30	ACTIVATION OF EQUINE OVOCYTES
AR028262A1 (en)	2003-04-30	HUMAN FAP-ALFA SPECIFIC ANTIBODIES